These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9056583)

  • 21. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
    Schall R
    Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence.
    Endrenyi L; Hao Y
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):450-7. PubMed ID: 9726700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Connections between average and individual bioequivalence.
    Munk A
    Stat Med; 2000 Oct; 19(20):2843-54. PubMed ID: 11033579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerable cost savings through the analysis of pooled plasma samples in bioequivalence studies that fail to show bioequivalence.
    Hundt HK; Schall R; Luus HG; Müller FO
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):331-6. PubMed ID: 8370632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S37-43. PubMed ID: 1601530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual bioequivalence--a regulatory update.
    Chen ML
    J Biopharm Stat; 1997 Mar; 7(1):5-11. PubMed ID: 9056581
    [No Abstract]   [Full Text] [Related]  

  • 37. A Bayesian approach to bioequivalence for the 2 x 2 changeover design.
    Selwyn MR; Dempster AP; Hall NR
    Biometrics; 1981 Mar; 37(1):11-21. PubMed ID: 7018605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis for bioequivalence review.
    Chow SC; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Some thoughts on individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):41-8. PubMed ID: 9056587
    [No Abstract]   [Full Text] [Related]  

  • 40. Joint equivalence of means and variances of two populations.
    Grieve AP
    J Biopharm Stat; 1998 Jul; 8(3):377-90. PubMed ID: 9741854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.